Search

Displaying results 1231 - 1240 of 4591 in total
  1. Drug

    Alpelisib

    go.drugbank.com/drugs/DB12015
    ApprovedInvestigational

    It works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival … [A179209] Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-

  2. Drug

    Amoxapine

    go.drugbank.com/drugs/DB00543
    Approved

    In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood.

  3. Drug

    Gallium nitrate

    go.drugbank.com/drugs/DB05260
    ApprovedInvestigational

    [A17097] GANITE, a product of gallium nitrate previously used to treat cancer-related hypercalcemia, was discontinued from marketing in the US for reasons other than safety or effectiveness.

  4. Drug

    Methaqualone

    go.drugbank.com/drugs/DB04833
    ApprovedIllicitWithdrawn

    The sedative-hypnotic activity was first noted by Indian researchers in the 1950s and in 1962 methaqualone itself was patented in the US by Wallace and Tiernan. … Clandestinely produced methaqualone is still seized by government agencies and police forces around the world.

  5. Drug

    Dichloralphenazone

    go.drugbank.com/drugs/DB01495
    ApprovedIllicit

    It is a US Schedule IV drug and its clinical use is limited.

  6. Drug

    Castor oil

    go.drugbank.com/drugs/DB11113
    ApprovedNutraceuticalVet approved

    Castor oil is a rich source of [DB02955], which represents up to 90% of the total castor oil content. … It also consists up to 4% linoleic, 3% oleic, 1% stearic, and less than 1% linolenic fatty acids [A31170].

  7. Drug

    AdPEDF

    go.drugbank.com/drugs/DB05138
    Experimental

    AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal ...

  8. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. … [L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test.

  9. Drug

    Pentobarbital

    go.drugbank.com/drugs/DB00312
    ApprovedVet approved

    It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. … A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally.

  10. Drug

    N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine

    go.drugbank.com/drugs/DB14196
    Approved

    N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine is a component of black rubber. It is also a dermatological sensitizer and allergen. Sensitivity to N-Cyclohexyl-N'-phenyl-1,4-phenylenediamine may be identified with a clinical patch test.